A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia

Citation
T. Isotalo et al., A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia, BJU INT, 88(1), 2001, pp. 30-34
Citations number
21
Categorie Soggetti
Urology & Nephrology
Journal title
BJU INTERNATIONAL
ISSN journal
14644096 → ACNP
Volume
88
Issue
1
Year of publication
2001
Pages
30 - 34
Database
ISI
SICI code
1464-4096(200107)88:1<30:ADRPPS>2.0.ZU;2-I
Abstract
Objective To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising fi nasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent. Patients and methods Fifty-five patients in acute urinary retention were tr eated as outpatients; they had a suprapubic catheter inserted and the SR-PL LA stent placed cystoscopically. After 2 weeks the patients were randomized to receive either finasteride 5 mg daily or placebo. They were assessed at baseline and at 6, 12 and 18 months for maximum urinary now rate, prostate volume and serum prostate-specific antigen (PSA). Results Nineteen patients completed the study while 36 discontinued. There was a statistically significant increase in the mean maximum flow rate, and a statistically significant decrease in the prostatic volume and serum PSA in the finasteride group. The same number of patients discontinued in both groups; the major reason for discontinuation was insufficient therapeutic response, Conclusions The major problems were discontinuation of treatment because th e response to therapy was insufficient, and uncontrolled breakdown of the s piral stent. To solve these problems, new configurations of bioabsorbable s tents are needed.